Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease
Why the study?
Does clopidogrel reduce mortality differently based on smoking status in patients with established cardiovascular disease?
Population
12,152 participants with established cardiovascular disease from the CHARISMA trial
Comparison
Clopidogrel vs Control group (not explicitly defined in abstract)
Design
Cohort, Patients were randomized to clopidogrel or control
Authors
Discussion
Loading...
Member takes
Implication
Clopidogrel-associated mortality reduction in current smokers with CVD should not yet change practice; leaves open differential efficacy by smoking status for prospective trials.
Structured PICO
Does clopidogrel reduce mortality differently based on smoking status in patients with established cardiovascular disease?
P
Population
12,152 participants with established cardiovascular disease from the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial
I
Intervention
Clopidogrel
C
Comparator
Control group (not explicitly defined in abstract)
O
Outcome
All-cause, cardiovascular, and cancer mortalityhard clinical
Clopidogrel therapy may be more effective in reducing mortality among current smokers with established cardiovascular disease, but it also confers a greater bleeding risk compared to nonsmokers.
Cite This Study
Berger et al. (2009) studied this question.